Cargando…
Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review
INTRODUCTION: HTX-019 [CINVANTI(®) (aprepitant injectable emulsion)] is a neurokinin 1 receptor antagonist (NK-1 RA) approved as a 30-min infusion for preventing acute and delayed chemotherapy-induced nausea and vomiting. HTX-019 has been generally well tolerated when administered as a 30-min infusi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824338/ https://www.ncbi.nlm.nih.gov/pubmed/30706408 http://dx.doi.org/10.1007/s12325-019-0877-3 |